FDA Approves VALPROATE SODIUM — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. received FDA approval for its intravenous valproate sodium generic, positioning the manufacturer to capitalize on the fast-growing antiepileptic market while entering direct competition with the branded Depacon product.